Although contemporary glioma clinical practice relies on multiple established biomarkers—including MGMT promoter methylation status, IDH, genetic alterations beyond 1p/19q and adjuvant therapies—these markers primarily focus on single therapeutic contexts or specific pathological subtypes. Here, IDH1 is linked to central nervous system cancer.